Is it time for a change at the top? Check out this paragraph from the May 2018 Newsletter.
"At the time of writing, the study continues to progress well, and we expect to report initial data in the second quarter of calendar 2018. The study is designed in such a way that the first information we learn will primarily be around safety, and in particular, the ‘maximum tolerated dose’, but the study will then move into an expansion component that we hope will provide some preliminary understanding of potential efficacy."
Progress well?? That would have been a good time James to let us know it's been tough recruiting patients. Why wait a week before your self-imposed deadline to inform investors?
Also, your press release could have been put together better by a fifth grader. Very disappointing.
KZA Price at posting:
60.0¢ Sentiment: Hold Disclosure: Held
